Preclinical

The goal of ACTIV is to develop a research strategy for prioritizing and speeding development of the most promising COVID-19 vaccines and treatments.

Overview

The Preclinical Working Group is focused on:

  • Establishing a centralized process and repository for harmonizing and sharing methods and evaluating animal models
  • Extending access to high-throughput screening facilities, especially in biosafety level 3 (BSL-3) labs
  • Increasing access to validated animal models
  • Enhancing comparison of approaches to identify informative assays
  • Generating a process to assess viral variant effects on vaccines and therapeutics, Learn more

Resources

ACTIV Preclinical Working Group: Small Animal Model Field Guide and Video Sessions

ACTIV Preclinical Working Group: Nonhuman Primate Field Guide

OpenData Portal Animal Models

Announcing
TRACE
 
The Tracking Resistance and Coronavirus Evolution 
initiative providing actionable information to assist
in monitoring and testing COVID-19 variants.